Webcast – update from the ODAC meeting, Sep 22, 2022
September 23, 2022, the Oncologic Drugs Advisory Committee (ODAC), of the US Food and Drug Administration (FDA), has finalized the discussion on the benefit-risk profile of Pepaxto® (melphalan flufenamide, also called melflufen). A majority of the panel considered that OCEAN did not confirm a favorable benefit-risk profile in the current indicated patient population.
Webcast for investors, analysts and media
Investors, analysts and media were invited to listen to a webcast presentation and participate in a following Q&A session on September 26, at 14:00 (CET). The event was hosted by CEO Jakob Lindberg, accompanied by CMO Klaas Bakker. The presentation was held in English and recorded.